Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27335502 | 0.90 | ALDH1A1 (0.46) | ALDH1A1CYP3A4KMT2ATDP1MEN1 | |
| SCHEMBL61037 | 0.84 | ALDH1A1 (0.50) | ALDH1A1CYP3A4KMT2ALMNASMN1; SMN2 | |
| SCHEMBL1232543 | 0.83 | ALDH1A1 (0.42) | ALDH1A1CYP3A4KMT2APTGDR2L3MBTL1 | |
| SCHEMBL5255523 | 0.82 | ALDH1A1 (0.65) | ALDH1A1CYP3A4KMT2ALMNASMN1; SMN2 | |
| SCHEMBL17491378 | 0.82 | LMNA (0.41) | ALDH1A1KMT2ATDP1MEN1LMNA | |
| SCHEMBL10890376 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP3A4KMT2AMEN1LMNA | |
| Trimethylammonium SCHEMBL23711255 | 0.80 | ALDH1A1 (0.46) | ALDH1A1CYP3A4KMT2ALMNASMN1; SMN2 | |
| Alcohol SCHEMBL11693989 | 0.80 | ALDH1A1 (0.46) | ALDH1A1CYP3A4KMT2AMEN1LMNA | |
| SCHEMBL1268573 | 0.79 | PTGDR2 (0.39) | ALDH1A1KMT2ATDP1MEN1LMNA | |
| SCHEMBL878376 | 0.79 | PPARG (0.58) | ALDH1A1KMT2ATDP1LMNAPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541626-B2 | Protecting/blocking the exocyclic amino function of purine nucleosides without effecting hydroxyl groups of sugar moieties via forming activated ester | ISIS PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | ALLAHABAD, UNIVERSITY OF (IN) | 2003-01-30 | — | — | US | claimed |
| WO-2002083702-A1 | PROCESS FOR SELECTIVE N-ACYLATION OF PURINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-9884885-B2 | Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2018-02-06 | — | — | US | disclosed |
| CN-103068834-B | Phosphoramidites for reverse RNA synthesis | 坎姆根公司 | 2016-10-26 | — | — | CN | disclosed |
| US-9273149-B2 | Methods and compositions for determining the purity of chemically synthesized nucleic acids | VERI-Q, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-8981076-B2 | Synthesis of N-FMOC protected deoxy nucleosides, ribo nucleosides, modified deoxy and ribo nucleosides, and phosphoramidites, and their use in oligonucleotide synthesis | CHEMGENES CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140193855-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | VERI-Q, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8697355-B2 | Methods and compositions for determining the purity of chemically synthesized nucleic acids | NORTH CAROLINA STATE UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| EP-1242459-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | NORTH CAROLINA STATE UNIVERSITY (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020045167-A1 | Used for detecting incomplete deprotection of a synthetic oligonucleotide by immunoassay | VERI-Q, INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001049745-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | UNIV NORTH CAROLINA STATE (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001049745-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | NORTH CAROLINA STATE UNIVERSITY (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0991777-A1 | NUCLEIC ACID BIOSENSOR DIAGNOSTICS | Krull, Ulrich J. (CA) | 2000-04-12 | — | — | EP | disclosed |
| US-6015886-A | ANTISENSE AGENTS WITH MODIFICATIONS INCLUDING P-ALKOXY AND 2'-O-METHYL GROUPS; NUCLEASE RESISTANT, ABILITY TO ACTIVATE BACTERIAL RIBONUCLEASE H, FORM STABLE DUPLEXES WITH RNA, AND HAVE STRONG HYDROPHOBICITY FOR EFFICIENT CELLULAR UPTAKE | CHEMGENES CORPORATION (US) | 2000-01-18 | — | — | US | disclosed |
| WO-1998058079-A1 | NUCLEIC ACID BIOSENSOR DIAGNOSTICS | KRULL ULRICH J (CA) | 1998-12-23 | — | — | WO | disclosed |
| US-4593033-A | Cardiovascular disorders | MERCK & CO., INC. (US) | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140193855-A1 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS | RNGTT, NOP2, DCLRE1B | ALDH1A1 4333/4885CYP3A4 4812/4885KMT2A 2366/4885 |
| US-20030022862-A1 | Process for selective N-acylation of purine nucleosides | PNP, NUDT1, ADAR | ALDH1A1 2917/4885CYP3A4 2872/4885KMT2A 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.